T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$4.95B |
| 2 |
Broadcom
AVGO
|
+$3.48B |
| 3 |
Microsoft
MSFT
|
+$2.66B |
| 4 |
Advanced Micro Devices
AMD
|
+$1.92B |
| 5 |
GE Aerospace
GE
|
+$1.49B |
Top Sells
| 1 |
Amazon
AMZN
|
+$3.79B |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$2.63B |
| 3 |
Apple
AAPL
|
+$2.46B |
| 4 |
Fiserv
FI
|
+$2.19B |
| 5 |
Eli Lilly
LLY
|
+$1.78B |
Sector Composition
| 1 | Technology | 34.76% |
| 2 | Financials | 12.08% |
| 3 | Healthcare | 10.97% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Communication Services | 10.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2976
BARK
BARK
$148M
| $54K | ﹤0.01% |
62,028
| – | – |
|
2977
DiaMedica Therapeutics
DMAC
$355M
| $53K | ﹤0.01% |
+13,368
| New | +$53K |
|
2978
Fate Therapeutics
FATE
$120M
| $53K | ﹤0.01% |
46,855
+8,806
| +23% | +$9.96K |
|
2979
loanDepot
LDI
$890M
| $53K | ﹤0.01% |
+41,283
| New | +$53K |
|
2980
Protalix BioTherapeutics
PLX
$140M
| $53K | ﹤0.01% |
+35,278
| New | +$53K |
|
2981
Gold Resource Corp
GORO
$115M
| $52K | ﹤0.01% |
84,700
| – | – |
|
|
LFT
2982
Lument Finance Trust
LFT
$123M
| $52K | ﹤0.01% |
+23,084
| New | +$52K |
|
2983
PLAYSTUDIOS Inc
MYPS
$120M
| $52K | ﹤0.01% |
39,525
| – | – |
|
2984
Zevia
ZVIA
$184M
| $52K | ﹤0.01% |
+15,945
| New | +$52K |
|
2985
Aemetis
AMTX
$137M
| $51K | ﹤0.01% |
20,463
-17,553
| -46% | -$43.7K |
|
2986
Rafael Holdings
RFL
$48.4M
| $51K | ﹤0.01% |
29,321
-410
| -1% | -$713 |
|
|
AIRJ
2987
Montana Technologies Corp
AIRJ
$285M
| $51K | ﹤0.01% |
+10,871
| New | +$51K |
|
2988
Protara Therapeutics
TARA
$122M
| $50K | ﹤0.01% |
+16,353
| New | +$50K |
|
|
TEAD
2989
Teads Holding Co. Common Stock
TEAD
$154M
| $49K | ﹤0.01% |
19,620
+3,087
| +19% | +$7.71K |
|
2990
Kartoon Studios
TOON
$38.6M
| $49K | ﹤0.01% |
65,355
-885
| -1% | -$664 |
|
2991
Zentalis Pharmaceuticals
ZNTL
$112M
| $49K | ﹤0.01% |
41,454
-28,231
| -41% | -$33.4K |
|
|
ILLR
2992
Triller Group Inc. Common Stock
ILLR
$113M
| $49K | ﹤0.01% |
+52,493
| New | +$49K |
|
2993
Karyopharm Therapeutics
KPTI
$55.9M
| $47K | ﹤0.01% |
+10,886
| New | +$47K |
|
2994
Rackspace Technology
RXT
$342M
| $47K | ﹤0.01% |
36,459
+8,521
| +30% | +$11K |
|
2995
Holley
HLLY
$354M
| $45K | ﹤0.01% |
22,221
+1,974
| +10% | +$4K |
|
2996
Coherus Oncology, Inc. Common Stock
CHRS
$151M
| $43K | ﹤0.01% |
58,482
+10,329
| +21% | +$7.6K |
|
2997
Lexeo Therapeutics
LXEO
$274M
| $42K | ﹤0.01% |
10,425
| – | – |
|
2998
Nkarta
NKTX
$143M
| $42K | ﹤0.01% |
25,196
+1,238
| +5% | +$2.06K |
|
2999
Tenaya Therapeutics
TNYA
$212M
| $42K | ﹤0.01% |
67,582
-21,988
| -25% | -$13.7K |
|
3000
InnovAge Holding
INNV
$589M
| $41K | ﹤0.01% |
+10,922
| New | +$41K |
|